I last covered Exelixis (EXEL) in May 2018. Since then, much has changed for the pharmaceutical industry as well as the company. Despite this, Exelixis continues to be an attractive pick in 2020.
Company overview
Exelixis is an oncology-focused biotechnology company with a market capitalization close to $5.9 billion. The company's commercial product portfolio comprises of three FDA-approved assets. The company’s lead asset, Cabometyx tablets, have been approved in the first-line and second-line advanced RCC (renal cell carcinoma) as well as second-line HCC (hepatocellular carcinoma) indications. Another drug, Cometriq capsules, has been